2 Information about tofacitinib

Information about tofacitinib

Marketing authorisation indication

Tofacitinib (Xeljanz, Pfizer), in combination with methotrexate, is indicated 'for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic drug (DMARD) therapy'.

Dosage in the marketing authorisation

The recommended dose of tofacitinib is 5 mg taken orally twice daily.

No dose adjustment is needed when tofacitinib is used with methotrexate. Treatment should be interrupted if a patient develops a serious infection until the infection is controlled.


The list price of a 56‑tablet pack of 5 mg tofacitinib is £690.03 (excluding VAT; British national formulary [BNF] online [accessed July 2018]).

The company has a commercial arrangement. This makes tofacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)